Alexandria Pharmaceuticals
Alexandria Pharmaceuticals operates in various business sectors.
Alexandria Pharmaceuticals (AXPH) - Net Assets
Latest net assets as of : EGP- EGP
Based on the latest financial reports, Alexandria Pharmaceuticals (AXPH) has net assets worth EGP- EGP as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (EGP-) and total liabilities (EGP-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | EGP- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Alexandria Pharmaceuticals - Net Assets Trend (None–None)
This chart illustrates how Alexandria Pharmaceuticals's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alexandria Pharmaceuticals (None–None)
The table below shows the annual net assets of Alexandria Pharmaceuticals from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Alexandria Pharmaceuticals's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Alexandria Pharmaceuticals Competitors by Market Cap
The table below lists competitors of Alexandria Pharmaceuticals ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Formuepleje Global Future
CO:FPIGFU
|
$157.52K |
|
NEWPALLADIUM
XBOT:NGPL-ETF
|
$157.61K |
|
UNITED UTILITIES GR - Dusseldorf Stock Exchang
DU:UUEC
|
$157.63K |
|
SparDanmark Invest Balance
CO:SDIBAL
|
$157.79K |
|
Maj Invest Opsparing
CO:MAJOPS
|
$157.46K |
|
Clarkson
LSE:CKN
|
$157.45K |
|
BENZ
NEO:BENZ
|
$157.44K |
|
BANK OF AMERICA CORPORATION CED
BA:BA-C
|
$157.30K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alexandria Pharmaceuticals's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Alexandria Pharmaceuticals's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Alexandria Pharmaceuticals utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Alexandria Pharmaceuticals's net assets metrics with peer companies in the same industry.
No peer company data available for comparison.